This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Oculus Innovative Sciences Announces Publication Of Results From Study Of Microcyn(R) Technology-Based Antipruritic Hydrogel In Treatment Of Atopic Dermatitis

Stocks in this article: OCLS

PETALUMA, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced publication of an open-label pilot study in which a Microcyn® Technology-based antipruritic hydrogel was evaluated in the treatment of atopic dermatitis. The study, appearing in the August 2012 issue of Cutis ( 2012;90:97-102), evaluated the effectiveness of Microcyn-based Atrapro™ antipruritic hydrogel in reducing the itch and clinical signs of atopic dermatitis when applied to affected areas of the body at least three times daily. A reduction in itch as early as day 3 was reported by 14 of 17 patients. At day 14 (end of the study), 82% and 88% of subjects experienced itch reduction according to patient and investigator assessments, respectively. By day 14 the overall body surface area of disease involvement was reduced on average by 58% from the baseline. This impact on the overall disease was also confirmed by the overall global assessment of the atopic dermatitis by the doctor. Mild dryness encountered by some patients readily resolved with emollient use.

Oculus licensed the Microcyn Technology-based products for treatment of atopic dermatitis in the United States to Quinnova Pharamceuticals in February 2011. The lead product, branded as Atrapro™ Antipruritic Hydrogel, was introduced to U.S. dermatologists in February 2012.

"The results of this study are consistent with the feedback we are receiving from dermatologists who have been using Atrapro since its introduction six months ago," said Jeffery Day, president of Quinnova Pharmaceuticals. "The physicians are enthused about the relatively rapid reduction in itch. As well, they appreciate the safety profile of Atrapro—without a single report of any serious adverse effects. Typically, atopic dermatitis treatments provide one or the other—some degree of efficacy or some degree of safety—but seldom both as is the case with Atrapro hydrogel."

An abstract of the Cutis study can be found at:  http://www.cutis.com/Article.aspx?ArticleId=c4dYnsdSxNM=

About Atopic Dermatitis

More than 15 million patients have symptoms of atopic dermatitis, characterized by itchy skin, which can lead to rash, redness, swelling, crusting and scaling. The disease affects up to 20 percent of infants and young children, who continue to have symptoms as adults with significant impact on their quality of life. The exact cause is unknown, but genetics are considered a key factor.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs